Research visual

Health Research

The impact of real world cardiovascular-related pharmacogenetic testing in an insured population

Billings J, Racsa PN, Bordenave K, Long CL, Ellis JJ. The impact of real world cardiovascular-related pharmacogenetic testing in an insured population. Int J Clin Pract. 2018 May 16:e13088. doi: 10.1111/ijcp.13088. [Epub ahead of print]

The impact of real-world cardiovascular-related pharmacogenetic testing in an insured population. - PubMed - NCBI

Diabetes therapeutic drug class: evaluating adherence and total cost of care

Runtas C, Bobbitt C, Burns S, Kendrick A, Dixon L, Lanham A. Diabetes therapeutic drug class: evaluating adherence and total cost of care. Poster presentation at: Pharmacy Quality Alliance Annual Meeting. May 16-18, 2018. Baltimore, MD.

http://apps.humana.com/marketing/documents.asp?file=3319823

Impact of a retrospective drug utilization review program on changing opioid prescribing behavior

Chiang J, Schwab P, McCulloch R, Brooks P, Rhodes C, Happe L. Impact of a retrospective drug utilization review program on changing opioid prescribing behavior. Poster presentation at: Academy of Managed Care and Specialty Pharmacy Annual Meeting. April 23-26, 2018. Boston, MA.

http://apps.humana.com/marketing/documents.asp?file=3319810

Characterizing Alzheimer’s disease in a Medicare Advantage population

Racsa P, Sehman M, Worley K, Ward MA, Ellis JJ. Characterizing Alzheimer’s disease in a Medicare Advantage population. Poster presentation at: 2018 Annual Scientific Meeting of the American Geriatrics Society. May 4, 2018. Orlando, FL.

Double threat: concurrent use of opioids and benzodiazepines

Pacholski EB, Weber JJ, Sandefur T, Cooley J, Gaddy RR. Double threat: Concurrent use of opioids and benzodiazepines. Poster presented at: Pharmacy Quality Alliance Annual Meeting. May 17-19, 2017. Baltimore, MD.

http://apps.humana.com/marketing/documents.asp?file=3288727

The effect of interactive reminders on medication adherence: A randomized trial.

Dai H, Mao D, Volpp KV, Pearce HE, Relish MJ, Lawnicki VF, Milkman K. The effect of interactive reminders on medication adherence: A randomized trial. Prev Med. 2017;103:98-102.

The effect of interactive reminders on medication adherence: A randomized trial. - PubMed - NCBI

Synchronized prescription refills and medication adherence: A retrospective claims analysis of Medicare patients on multiple maintenance medications

Doshi JA, Lim R, Li P, Young PP, Lawnicki VF, Troxel A, Volpp K. Synchronized prescription refills and medication adherence: A retrospective claims analysis of Medicare patients on multiple maintenance medications. Am J Manag Care. 2017;23(2):98-104.

Synchronized prescription refills and medication adherence: a retrospective claims analysis. - PubMed - NCBI

Impact of antidepressant medication adherence on health-related quality of life among older adults with newly diagnosed Major Depressive Disorder

Trevino L, Cordier T, Renda A, Gresky D, Ruble M. Impact of antidepressant medication adherence on health-related quality of life among older adults with newly diagnosed Major Depressive Disorder. Poster presentation at: American Psychiatric Association Annual Meeting. May 20-24, 2017. San Diego, CA.

http://apps.humana.com/marketing/documents.asp?file=3114657

Capitalizing on fresh starts does not impact the effectiveness of medication adherence reminders: a randomized trial

Dai H, Mao D, Riis J, Volpp KG, Relish MJ, Lawnicki VF, Milkman KL. Capitalizing on fresh starts does not impact the effectiveness of medication adherence reminders: a randomized trial. JAMA Cardiol. Published online February 8, 2017. doi:10.1001/jamacardio.2016.5794.

Effectiveness of Medication Adherence Reminders Tied to "Fresh Start" Dates: A Randomized Clinical Trial. - PubMed - NC…

Leveraging pharmacy retail clinic proximity and predictive models to reduce non-emergent emergency department utilization

Zhao Y, Schilling S, Johnson SK, Haugh G, Fan J, Singh H, Chui S, Gopal V. , Leveraging pharmacy retail clinic proximity and predictive models to reduce non-emergent emergency department utilization. Poster presentation at: American Pharmacists Association Annual Meeting & Exposition. March 24-27, 2017. San Francisco, CA.

http://apps.humana.com/marketing/documents.asp?file=3103555

Adherence, persistence, and healthcare costs for patients receiving dipeptidyl peptidase-4 inhibitors

Rascati K, Worley K, Meah Y, Everhart D. Adherence, persistence, and healthcare costs for patients receiving dipeptidyl peptidase-4 inhibitors. J Manage Care Pharm. 2017;23(3):299-306.

Adherence, Persistence, and Health Care Costs for Patients Receiving Dipeptidyl Peptidase-4 Inhibitors. - PubMed - NCBI

Successful implementation of a medication bundle for secondary prevention of cardiovascular outcomes among individuals with Medicare Advantage coverage

Morgan T, Das N, Megibben J, Gumpina R, Hyppolite-Oyadiran C, Simmons J, Hernandez, Y, Ryu J. Successful implementation of a medication bundle for secondary prevention of cardiovascular outcomes among individuals with Medicare Advantage coverage. Poster presentation at: AcademyHealth 9th Annual Conference on the Science of Dissemination and Implementation. December 14, 2016. Washington, DC.

http://apps.humana.com/marketing/documents.asp?file=3081065

Incidence, prevalence and treatment patterns of Alzheimer's disease and cognitive impairment-related conditions among 4.5 million members of a U.S. health plan

Ellis JJ, Nsiah I, Brown C, Murty C, Moore C, Beucker R, Esterly L, Saverno KR. Incidence, prevalence and treatment patterns of Alzheimer's disease and cognitive impairment-related conditions among 4.5 million members of a U.S. health plan. Poster presentation at: Academy of Managed Care Pharmacy Nexus 2016 Conference. October 4, 2016; National Harbor, MD.

http://apps.humana.com/marketing/documents.asp?file=3068091

PD-1 inhibitor prescribing patterns and utilization trends in a large national health plan

Ems D, Kennedy K, Gregory F, et al. PD-1 inhibitor prescribing patterns and utilization trends in a large national health plan. Poster presentation at: Academy of Managed Care Pharmacy Nexus 2016 Conference. October 4, 2016; National Harbor, MD.

http://apps.humana.com/marketing/documents.asp?file=3058757

Refill patterns with oral oncolytic medications

Dye JT, Murty S, Nsiah I, Kennedy K, Whisman T, Worley K. Refill patterns with oral oncolytic medications. J Clin Oncol. 2016;34(suppl; abstr e18216).

Refill patterns with oral oncolytic medications. | 2016 ASCO Annual Meeting | Abstracts | Meeting Library

Synchronized prescription refill program to improve medication adherence: a prospective study

Doshi JA, Lim R, Li P, Young PP, Lawnicki VF, State JJ, Troxel A, Volpp K. Synchronized prescription refill program to improve medication adherence: a prospective study. Health Affairs. 2016;35(8):1504-1512.

http://content.healthaffairs.org/content/35/8/1504.abstract

 

 

 

 

 

Does hepatitis C treatment adherence affect the risk of liver transplant? A historical cohort study

Ems E, Rasca P, Anderson C, Gregory F, Worley K, Brill J, Holt W. Does hepatitis C treatment adherence affect risk of liver transplantation? A historical cohort study. J Manag Care Pharm. 2016;22(7):863-71.

Does Hepatitis C Treatment Adherence Affect Risk of Liver Transplantation? A Historical Cohort Study. - PubMed - NCBI

Comparative effectiveness analysis of rapid-acting insulin therapies in a large national health plan

Rasca P, Meah Y, Ellis JJ, Saverno K. Comparative effectiveness analysis of rapid-acting insulin therapies in a large national health plan. J Manag Care Pharm. 2017:23(3):291-298.

https://www.ncbi.nlm.nih.gov/pubmed/?term=Comparative+effectiveness+of+rapid-acting+insulins+in+adults+with+diabete

Comparison of utilization and outcomes in patients with hemophilia receiving plasma-derived factors versus recombinant factors

Nsiah I, Aten A, Ellis J, Gregory F, Saverno, K. Comparison of utilization and outcomes in patients with hemophilia receiving plasma-derived factors versus recombinant factors. Poster presentation at: Academy of Managed Care & Specialty Pharmacy Annual Meeting. April 19-22, 2016; San Francisco, CA.

http://apps.humana.com/marketing/documents.asp?file=2859584

Antipsychotic prescribing patterns in a Medicare Advantage population of older individuals with dementia

Kester R, Unützer J, Hogan D, Huang H. Antipsychotic prescribing patterns in a Medicare Advantage population of older individuals with dementia. Poster presentation at: American Association for Geriatric Psychiatry Annual Meeting. March 17-20, 2016; Washington DC.

http://apps.humana.com/marketing/documents.asp?file=2882113

Impact of out-of-pocket costs on initial and subsequent prescription refills among new initiators of biologic therapies indicated for RA

Hopson S, Saverno K, Liu LZ, AL-Sabbagh A, Orazem J, Pasquale MK. Impact of out-of-pocket costs on initial and subsequent prescription refills among new initiators of biologic therapies indicated for RA. JMCP 2016; 22(2):122-130.

Use of add-on treatment to metformin monotherapy for patients with type 2 diabetes and suboptimal glycemic control: a U.S. database study

Yu S, Schwab P, Bian B, Radican L, Tuncelli K. Use of add-on treatment to metformin monotherapy for patients with type 2 diabetes and suboptimal glycemic control: a U.S. database study. J Manag Care Spec Pharm. 2016;22(3):272-80.

http://www.jmcp.org/doi/pdf/10.18553/jmcp.2016.22.3.272

Patterns of care in patients with metastatic renal cell carcinoma among a US payer population

Miller LA, Stemkowski S, Saverno K, Lane D, Tao Z, Hackshaw M, Loy B. Patterns of care in patients with metastatic renal cell carcinoma among a US payer population. J Manag Care Spec Pharm, 2016;22(3):219-226

http://www.jmcp.org/doi/pdf/10.18553/jmcp.2016.22.3.219

Evaluation of molecular testing patterns in metastatic non-small cell lung cancer at a large US health plan

MacLean EA, Louder AM, Saverno KR, Smith G, Mardekian J, Bruins C, Ward M, Sweetman RW, Pasquale M. Evaluation of molecular testing patterns in metastatic non-small cell lung cancer at a large US health plan. American Journal of Managed Care 2016; 22(2): e60-e67.

Evaluation of molecular testing patterns in metastatic non-small cell lung cancer at a large U.S. health plan. | 2014 AS…

Early treatment revisions by addition or switch for type 2 diabetes: impact on glycemic control, diabetic complications, and healthcare costs

Schwab P, Saundankar V, Bouchard J, Wintfeld N, Suehs B, Moretz C, Allen E, DeLuzio A. Early treatment revisions by addition or switch for type 2 diabetes: impact on glycemic control, diabetic complications, and healthcare costs. BMJ Open Diabetes Research and Care 2016;4:e000099. doi:10.1136/bmjdrc-2015-000099

Early treatment revisions by addition or switch for type 2 diabetes: impact on glycemic control, diabetic complications,…

COPD exacerbations associated with the modified medical research council scale and COPD assessment test among Humana’s medicare members

Pasquale MK, Xu Y, Baker CL, Zou KH, Teeter JG, Renda AM, Davis CC, Lee TC, Bobula J. COPD exacerbations associated with the modified medical research council scale and COPD assessment test among Humana’s medicare members. International Journal of COPD 2016; 11:111-121.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716734/pdf/copd-11-111.pdf

Effect of new drug therapies on current metastatic melanoma treatment patterns

Kennedy K, Murty S, Dye J, Whisman T, Worley K. Effect of new drug therapies on current metastatic melanoma treatment patterns. J Natl Compr Canc Netw. 2016;14(5.5):e1-e30.

http://apps.humana.com/marketing/documents.asp?file=2852434

Trusted third party influencers for medication adherence

Relish M, Young P, Vogel V, et al. Trusted third party influencers for medication adherence. Circ Cardiovasc Qual Outcomes. 2016;9(Suppl 2):A266.

http://apps.humana.com/marketing/documents.asp?file=2834104

Validation of febrile seizures identified in the mini-sentinel post-licensure rapid immunization safety monitoring (PRISM) system

Kawai AT, Martin D, McMahill-Walraven CN, et al. Validation of febrile seizures identified in the mini-sentinel post-licensure rapid immunization safety monitoring (PRISM) system. Poster presentation at: Infectious Disease Week. October 8-14, 2014; Philadelphia, PA.

http://apps.humana.com/marketing/documents.asp?file=2574559

Utilization of paliperidone long-acting injection among Medicare Advantage and Medicare Prescription Drug Plan members

Suehs B, Li Y, Howe A, et al. Utilization of paliperidone long-acting injection among Medicare Advantage and Medicare Prescription Drug Plan members. Poster presentation at: International Society for Pharmacoeconomics and Outcomes Research 17th Annual International Meeting. June 2-6, 2012; Washington, DC.

http://apps.humana.com/marketing/documents.asp?file=2574546

Understanding patient preferences associated with the use of biologic therapies for RA: results of a conjoint analysis

Louder A, Saverno K, Singh A. et al. Understanding patient preferences associated with the use of biologic therapies for RA: results of a conjoint analysis. Poster presentation at: American College of Rheumatology Annual Meeting. November 14-19, 2014; Boston, MA.

http://apps.humana.com/marketing/documents.asp?file=2542995

Retrospective cohort analysis of the patterns and predictors of metformin treatment change in a Medicare Advantage patient population from a large national health plan

Hazel-Fernandez L, Xu Y, Moretz C, et al. Retrospective cohort analysis of the patterns and predictors of metformin treatment change in a Medicare Advantage patient population from a large national health plan. Poster presentation at: International Society for Pharmacoeconomics and Outcomes Research 19th Annual International Meeting. May 31-June 4, 2014; Montreal, QC, Canada.

http://apps.humana.com/marketing/documents.asp?file=2574507

Relative adherence across sites of care for infliximab patients with Crohn's disease

Michels SL, Eyck T, Vanderpoel J, et al. Relative adherence across sites of care for infliximab patients with Crohn's disease. Poster presentation at: International Society for Pharmacoeconomics and Outcomes Research 19th Annual International Meeting. May 31-June 4, 2014; Montreal, QC, Canada.

http://apps.humana.com/marketing/documents.asp?file=2574494

Potential drug-drug interactions and opioid use among painful diabetic peripheral neuropathy Medicare members newly started on pregabalin or duloxetine

Eyck LT, Sadosky A, Ellis J, et al. Potential drug-drug interactions and opioid use among painful diabetics peripheral neuropathy Medicare members newly started on pregablin or duloxetine. Poster presentation at: American Diabetes Association 74th Scientific Sessions. June 13-17, 2014; San Francisco, CA.

http://apps.humana.com/marketing/documents.asp?file=2574325

Patterns of lubiprostone utilization in a large managed care population

Sussman D, Tamariz L, Droege M, Harkins T, et al. Patterns of lubiprostone utilization in a large managed care population. Poster presentation at: Digestive Disease Week. May 1-5, 2010; New Orleans, LA.

http://apps.humana.com/marketing/documents.asp?file=2574312

Patterns of lubiprostone use and costs in a large health benefits company

Sussman D, Tamariz L, Droege M, Harkins T, et al. Patterns of lubiprostone use and costs in a large health benefits company. Poster presentation at: International Society for Pharmacoeconomics and Outcomes Research 15th Annual International Meeting. May 15-19, 2010; Atlanta, GA.

http://apps.humana.com/marketing/documents.asp?file=2574286

Out-of-pocket costs and prescription reversals: the case of oral linezolid

Pasquale M, Louder AM, Deminski MC, et al. Out-of-pocket costs and prescription reversals: the case of oral linezolid. Poster presentation at: Academy of Managed Care Pharmacy 25th Annual Meeting and Expo. April 2-5, 2013; San Diego, CA

http://apps.humana.com/marketing/documents.asp?file=2574273

Opportunities and challenges in providing face-to-face and telephonic MTM services to a commercially-insured population

Crawford S, Touchette DR, Sharp LK, et al. Opportunities and challenges in providing face-to-face and telephonic MTM services to a commercially-insured population. Poster presentation at: Academy of Managed Care Pharmacy Nexus. October 7-10, 2014; Boston, MA.

http://apps.humana.com/marketing/documents.asp?file=2645188

Impact of roflumilast on COPD exacerbations, healthcare utilization and costs in a Medicare Advantage population

Ellis J, Sun SX, Moll K, et al. Impact of roflumilast on COPD exacerbations, healthcare utilization and costs in a Medicare Advantage population. Poster presentation at: American Thoracic Society International Conference. May 16-21, 2014; San Diego, CA.

http://apps.humana.com/marketing/documents.asp?file=2574234

Impact of patient behaviors and attitudes on teriparatide adherence in a Medicare Part D population

Hazel-Fernandez L, Foater SA, Uribe C, et al. Impact of patient behaviors and attitudes on teriparatide adherence in a Medicare Part D population. Poster presentation at: International Society for Pharmacoeconomics and Outcomes Research 16th Annual International Meeting. May 21-25, 2011; Baltimore, MD.

http://apps.humana.com/marketing/documents.asp?file=2574221

Impact of a step-therapy policy restriction for pregabalin on health care utilization and expenditures in a commercial population

Louder A, Udall M, Suehs BT, et al. Impact of a step-therapy policy restriction for pregabalin on health care utilization and expenditures in a commercial population. Poster presentation at: Academy of Managed Care Pharmacy Educational Conference. October 3-5, 2012; Cincinnati, OH.

http://apps.humana.com/marketing/documents.asp?file=2574208

Identifying schizophrenia patients at high-risk for antipsychotic nonadherence using the assessment for quality improvement and risk evaluation tool

Muser E, Slabaugh SL, Louder A, Patel N. Identifying schizophrenia patients at high-risk for antipsychotic nonadherence using the assessment for quality improvement and risk evaluation tool. Poster presentation at: International Society for Pharmacoeconomics and Outcomes Research 18th Annual International Meeting. May 18-22, 2013; New Orleans, LA.

http://apps.humana.com/marketing/documents.asp?file=2574195

Healthcare costs by level of adherence for infliximab patients with Crohn's disease

Michels SL, Eyck T, Vanderpoel J, et al. Healthcare costs by level of adherence for infliximab patients with Crohn's disease. Poster presentation at: International Society for Pharmacoeconomics and Outcomes Research 19th Annual International Meeting. May 31-June 4, 2014; Montreal, QC, Canada.

http://apps.humana.com/marketing/documents.asp?file=2573974

Delayed treatment modifications for patients with type 2 diabetes mellitus (T2DM) with very poor glycemic control

Schwab P, Saundankar V, Bouchard J, et al. Delayed treatment modifications for patients with type 2 diabetes mellitus (T2DM) with very poor glycemic control. Poster presentation at: International Society for Pharmacoeconomics and Outcomes Research 19th Annual International Meeting. May 31-June 4, 2014; Montreal, QC, Canada.

http://apps.humana.com/marketing/documents.asp?file=2345278

Concomitant statin use with ezetimibe or colesevelam for treatment of hypercholesterolemia

Ye X, Bays H, Schwab P, et al. Concomitant statin use with ezetimibe or colesevelam for treatment of hypercholesterolemia. Poster presentation at: International Society for Pharmacoeconomics and Outcomes Research 18th Annual International Meeting. May 18-22, 2013; New Orleans, LA.

http://apps.humana.com/marketing/documents.asp?file=2573922

Comparative outcomes of patients newly initiating first-generation vs. second-generation tyrosine kinase inhibitors for chronic myeloid leukemia

Ward MA, Fang G, Richards K, et al. Comparative outcomes of patients newly initiating first-generation vs. second-generation tyrosine kinase inhibitors for chronic myeloid leukemia. Poster presentation at: Academy of Managed Care Pharmacy Nexus. October 7-10, 2014; Boston, MA.

http://apps.humana.com/marketing/documents.asp?file=2452333

Comorbidity burden, health care resource utilization, and health care cost among Medicare Advantage members with Alzheimer's disease

Suehs B, Davis CD, Shah SN, et al. Comorbidity burden, health care resource utilization, and health care cost among Medicare Advantage members with Alzheimer's disease. Poster presentation at: Academy of Managed Care Pharmacy Educational Conference. October 3-5, 2012; Cincinnati, OH.

http://apps.humana.com/marketing/documents.asp?file=2573909

Clinical and economic outcomes associated with teriparatide adherence in Medicare Part D recipients: a retrospective cohort study

Hazel-Fernandez L, Louder AM, Foater SA, et al. Clinical and economic outcomes associated with teriparatide adherence in Medicare Part D recipients: a retrospective cohort study. Poster presentation at: International Society for Pharmacoeconomics and Outcomes Research 17th Annual International Meeting. June 2-6, 2012; Washington, DC.

http://apps.humana.com/marketing/documents.asp?file=2573896

Claims-based algorithm targeting Medicare Advantage Prescription Drug (MAPD) members with chronic obstructive pulmonary disease (COPD) for care intervention

Worley K, Shenolikar R, Song F, et al.  Claims-based algorithm targeting Medicare Advantage Prescription Drug (MAPD) members with chronic obstructive pulmonary disease (COPD) for care intervention. Poster presentation at: American Society of Health Systems Pharmacists Midyear Clinical Meeting; December 4-8, 2011; New Orleans, LA.

http://apps.humana.com/marketing/documents.asp?file=2573883

Anticoagulation treatment in high risk Medicare Advantage patients with non-valvular atrial fibrillation

Dye J, Louder A, Pasquale M. Anticoagulation treatment in high risk Medicare Advantage patients with non-valvular atrial fibrillation. Poster presentation at: American Heart Association Scientific Sessions. November 15-19, 2014; Chicago, IL.

http://apps.humana.com/marketing/documents.asp?file=2573844

Analysis of first dose observation data for MS treatment with fingolimod (DX14)

Schwab P, Zhou Y, Stemkowski S, et al. Analysis of first dose observation data for MS treatment with fingolimod. Poster presentation at: The Consortium for Multiple Sclerosis Centers and Americas Committee for Treatment and Research in Multiple Sclerosis 5th Cooperative Meeting. May 30-June 2, 2012; San Diego, CA.

http://apps.humana.com/marketing/documents.asp?file=2645149

All-cause and driver-specific healthcare resource utilization in newly diagnosed non-valvular atrial fibrillation patients newly initiating dabigatran and warfarin

Michels SL, Sheer R, Ghate SR, Moretz C, Wang C, Stemkowski S, Sander SD, Andrews G. All-cause and driver-specific healthcare resource utilization in newly diagnosed non-valvular atrial fibrillation patients newly initiating dabigatran and warfarin. Poster presentation at: Academy of Managed Care Pharmacy 26th Annual Meeting & Expo. April 1-4, 2014; Tampa, FL.

http://apps.humana.com/marketing/documents.asp?file=2332018

A retrospective cohort study to identify Medicare members at risk of low adherence to glaucoma medication

Sheer R, Bunniran S, Uribe C. A retrospective cohort study to identify Medicare members at risk of low adherence to glaucoma medication. Poster presentation at: Academy of Managed Care Pharmacy Nexus. October 7-10, 2014; Boston, MA.

http://apps.humana.com/marketing/documents.asp?file=2645136

Risk of liver transplant in treated vs. untreated hepatitis C

Ems D, Racsa P, Anderson C, Gregory F, Worley K. Risk of liver transplant in treated vs. untreated hepatitis C. Poster presentation at: International Society for Pharmacoeconomics and Outcomes Research 20th Annual International Meeting. May18-20, 2015; Philadelphia, PA.

https://apps.humana.com/marketing/documents.asp?file=2637778

Prescribing practices of antidepressant medications for treatment of major depressive disorder (MDD) among insured members (n=68,394)

Treviño LA, Treviño K,  Racsa P,  Biggan JR,  Gresky D, Gopal V. Prescribing practices of antidepressant medications for treatment of major depressive disorder (MDD) among insured members (n=68,394). Poster presentation at: American Psychiatric Association 168th Annual Meeting. May 16-20, 2015; Toronto, ON, Canada.

http://apps.humana.com/marketing/documents.asp?file=2640079

Comparing costs and health outcomes in initial therapy with sunitinib versus pazopanib for renal cell carcinoma

Racsa P, Worley K, Whisman T. Comparing costs and health outcomes in initial therapy with sunitinib versus pazopanib for renal cell carcinoma. J Natl Compr Canc Netw. 2015;13:625-26.

https://apps.humana.com/marketing/documents.asp?file=2584023

An examination of influenza vaccination timing and risk of infection

Glasheen W, Renda A. An examination of influenza vaccination timing and risk of infection. Poster presentation at: Preventative Medicine 2015. February25-28, 2015; Atlanta, GA.

http://apps.humana.com/marketing/documents.asp?file=2583061

Podcast: https://www.brainshark.com/humana/fluvaccine

Treatment rates and prevalence of high priority comorbidities for treatment initiation in people with hepatitis C

Racsa P, Ems D, Anderson C, Gregory F, Worley K. Treatment rates and prevalence of high priority comorbidities for treatment initiation in people with hepatitis C. Poster presentation at: AcademyHealth Annual Research Meeting. June 14-16, 2015; Minneapolis, MN.

http://apps.humana.com/marketing/documents.asp?file=2645240

Prescribing practices of antidepressant medications for treatment of major depressive disorder (MDD) among insured members (n=68,394)

Treviño LA, Treviño K, Racsa P, Biggan JR, Gresky D, Gopal V. Prescribing practices of antidepressant medications for treatment of major depressive disorder (MDD) among insured members (n=68,394). Poster (encore) presentation at: American Psychiatric Association Institute on Psychiatric Services, The Mental Health Services Conference.  October 8-11, 2015; New York, NY.

http://apps.humana.com/marketing/documents.asp?file=2771561

Characteristics of and medication adherence for diabetic patients receiving dipeptidyl peptidase-4 inhibitors in the US Medicare and commercial insurance plans

Rascati K, Worley K, Meah Y, Everhart D. Characteristics of and medication adherence for diabetic patients receiving dipeptidyl peptidase-4 inhibitors in the US Medicare and commercial insurance plans. Poster presentation at: Academy of Managed Care Pharmacy Nexus Conference. October 26-29, 2015; Orlando, FL.

http://apps.humana.com/marketing/documents.asp?file=2799836

2014 trends in the Medicare Part D coverage gap

Mitchell B, Preston N, Relish M. 2014 trends in the Medicare Part D coverage gap. Poster presentation at: Academy of Managed Care Pharmacy Nexus conference. October 26-29, 2015; Orlando, FL.

http://apps.humana.com/marketing/documents.asp?file=2803008

Costs for diabetic patients receiving dipeptidyl peptidase-4 (DPP-4) inhibitors in US Medicare and commercial insurance plans

Rascati KL, Worley K, Everhart D, Meah Y. Costs for diabetic patients receiving dipeptidyl peptidase-4 (DPP-4) inhibitors in US Medicare and commercial insurance plans. Poster presentation at: International Society for Pharmacoeconomics and Outcomes Research 18th Annual European Congress. November 7-11, 2015; Milan, Italy.

http://apps.humana.com/marketing/documents.asp?file=2819232

Do people who are adherent to their medications have fewer unhealthy days?

Cordier T, Slabuagh SL, Young P, Havens, E, Goapl V, Prewitt T. Do people who are adherent to their medications have fewer unhealthy days? Podium presentation at: Preventive Medicine. February 27, 2016; Washington DC.

http://apps.humana.com/marketing/documents.asp?file=2838862

Association between osteoporosis treatment change and total direct healthcare costs in Medicare Advantage Prescription Drug (MAPD) plan

Ward M.  Association between osteoporosis treatment change and total direct healthcare costs in Medicare Advantage Prescription Drug (MAPD) plan. Podium presentation at: Academy of Managed Care Pharmacy Educational Conference. October, 2011; Atlanta, GA.

Associations between osteoporosis treatment change, adherence, and incident fractures among members in a Medicare Advantage Prescription Drug (MAPD) plan

Xu Y.  Associations between osteoporosis treatment change, adherence, and incident fractures among members in a Medicare Advantage Prescription Drug (MAPD) plan. Podium presentation at: American Society for Bone and Mineral Research. September, 2011; San Diego, CA.

Bridging the gap: impact of Part D low income subsidy coverage or branded gap coverage on medication continuity among osteoporosis patients treated with teriparatide

Uribe C.  Bridging the gap: impact of Part D low income subsidy coverage or branded gap coverage on medication continuity among osteoporosis patients treated with teriparatide. Podium presentation at: AcademyHealth. June, 2009; Chicago, IL.

Electronically-transmitted prescriptions involved in primary prescription abandonment

Ellis J.  Electronically-transmitted prescriptions involved in primary prescription abandonment. Podium presentation at: Academy of Managed Care Pharmacy Nexus Meeting. October, 2014; Boston, MA.

Evaluating allopurinol therapy and serum uric acid (sUA) levels in Medicare beneficiaries with gout

Ward M.  Evaluating allopurinol therapy and serum uric acid (sUA) levels in Medicare beneficiaries with gout. Podium presentation at: American Geriatrics Society. May, 2012; Seattle, WA.

Evaluating characteristics of electronic prescriptions using pharmacy claims data

Slabaugh S. Evaluating characteristics of electronic prescriptions using pharmacy claims data.  Podium presentation at: Academy of Managed Care’s Annual Meeting & Showcase. April, 2012; San Francisco, CA.

Evaluating primary adherence using electronic prescription transactions

Constantino M.  Evaluating primary adherence using electronic prescription transactions. Podium presentation at: Academy of Managed Care Pharmacy Annual Meeting. April, 2011; Minneapolis, MN.

Evaluation of narcotic/acetaminophen prescription patterns and acetaminophen toxicity in a managed care population

Xu Y. Evaluation of narcotic/acetaminophen prescription patterns and acetaminophen toxicity in a managed care population. Podium presentation at: Academy of Managed Care Pharmacy Annual Meeting. April, 2010; San Diego, CA.

Evaluation of PQA draft measures of MTM performance

Ward M.  Evaluation of PQA draft measures of MTM performance. Podium presentation at: Academy of Managed Care Pharmacy Annual Meeting. April, 2011; Minneapolis, MN.

Evaluation of the impact of consumer messaging on medication treatment patterns

Louder A.  Evaluation of the impact of consumer messaging on medication treatment patterns. Podium presentation at: Academy of Managed Care Pharmacy Annual Meeting. April, 2010; San Diego, CA.

Impact of celecoxib restrictions in Medicare beneficiaries with arthritis

Louder A.  Impact of celecoxib restrictions in Medicare beneficiaries with arthritis. Podium presentation at: Academy of Managed Care Pharmacy Educational Conference. October, 2010. St. Louis, MO.

Impact of generic conversion on cardiovascular medication adherence: a retrospective analysis in a managed care database

Ward M. Impact of generic conversion on cardiovascular medication adherence: a retrospective analysis in a managed care database. Podium presentation at: Academy of Managed Care Pharmacy Annual Meeting & Showcase. April, 2008; San Francisco, CA.

Impact of medication therapy management on formulary tier changes in a commercial population

Ward M. Impact of medication therapy management on formulary tier changes in a commercial population. Podium presentation at: Academy of Managed Care Pharmacy Educational Conference. October, 2008; Kansas City, Kansas.

Impact of out-of-pocket costs on initial and subsequent prescription refills among new initiators of biologic therapies indicated for RA

Saverno K, Pasquale M. Impact of out-of-pocket costs on initial and subsequent prescription refills among new initiators of biologic therapies indicated for RA. Oral presentation presented at: Academy of Managed Care Pharmacy. October, 2014; Boston, MA.

http://www.jmcp.org/doi/pdf/10.18553/jmcp.2016.14261

Impact of the Affordable Care Act on medication adherence in a population of Medicare Part D beneficiaries

Ward M.  Impact of the Affordable Care Act on medication adherence in a population of Medicare Part D beneficiaries. Oral presentation presented at: Academy of Managed Care Pharmacy Annual Meeting & Showcase. April, 2012; San Francisco, CA.

Patterns of osteoporosis treatment change in a Medicare Advantage prescription drug (MAPD) plan

Xu Y. Patterns of osteoporosis treatment change in a Medicare Advantage Prescription Drug (MAPD) plan. Oral presentation presented at: Academy of Managed Care Pharmacy Annual Meeting & Showcase. April, 2011;  Minneapolis, MN.

Pharmacologic management of bipolar disorder in a Medicare Advantage population

Huang H, Gören JL, Chan YF, et al. Pharmacologic management of bipolar disorder in a Medicare Advantage population. Psychosomatics. 2014;55(6):572-7.

Pharmacologic management of bipolar disorder in a Medicare Advantage population. - PubMed - NCBI

Depression care and treatment in a chronically ill Medicare population

Huang H, Russo J, Bauer AM, et al. Depression care and treatment in a chronically ill Medicare population. Gen Hosp Psychiatry. 2013;35(4):382-6.

Depression care and treatment in a chronically ill Medicare population. - PubMed - NCBI

Validity of diagnostic codes to identify cases of severe acute liver injury in the U.S. Food and Drug Administration's Mini-Sentinel Distributed Database

Lo Re V 3rd, Haynes K, Goldberg D, et al. Validity of diagnostic codes to identify cases of severe acute liver injury in the US Food and Drug Administration's Mini-Sentinel Distributed Database. Pharmacoepidemiol Drug Saf. 2013;22(8):861-72.

http://www.ncbi.nlm.nih.gov/pubmed/23801638

Validation of anaphylaxis in the Food and Drug Administration’s Mini-Sentinel

Walsh KE, Cutrona SL, Foy S, et al. Validation of anaphylaxis in the Food and Drug Administration's Mini-Sentinel. Pharmacoepidemiol Drug Saf. 2013;22(11):1205-13.

Validation of anaphylaxis in the Food and Drug Administration's Mini-Sentinel. - PubMed - NCBI

The prevalence of diagnosed opioid abuse in commercial and Medicare managed care populations

Dufour R, Joshi AV, Pasquale MK, et al. The prevalence of diagnosed opioid abuse in commercial and Medicare managed care populations. Pain Pract. 2014;14(3):E106-15.

The prevalence of diagnosed opioid abuse in commercial and Medicare managed care populations. - PubMed - NCBI

The organizational structure and governing principles of the Food and Drug Administration's Mini-Sentinel pilot program

Forrow S, Campion DM, Herrinton LJ, et al. The organizational structure and governing principles of the Food and Drug Administration's Mini-Sentinel pilot program. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):12-7.

The organizational structure and governing principles of the Food and Drug Administration's Mini-Sentinel pilot program.…

Risk for fractures with centrally acting muscle relaxants: an analysis of a national Medicare Advantage claims database

Golden AG, Ma Q, Nair V, Florez HJ, Roos BA. Risk for fractures with centrally acting muscle relaxants: an analysis of a national Medicare Advantage claims database. Ann Pharmacother. 2010;44(9):1369-75.

Risk for fractures with centrally acting muscle relaxants: an analysis of a national Medicare Advantage claims database.…

Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage prescription drug plan population

Bergeson JG, Worley K, Louder A, Ward M, Graham J. Retrospective database analysis of the impact of prior authorization for Type 2 Diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population. J Manag Care Pharm.2013;19(5):374-84.

Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care cost…

Pharmacist-provided telephonic medication therapy management in an MAPD plan

Ward MA, Xu Y. Pharmacist-provided telephonic medication therapy management in an MAPD plan. Am J Manag Care. 2011;17(10):e399-409.

Pharmacist-provided telephonic medication therapy management in an MAPD plan. - PubMed - NCBI

Persistence with biologic therapies in the Medicare coverage gap

Tamariz L, Uribe CL, Luo J, et al. Persistence with biologic therapies in the Medicare coverage gap. Am J Manag Care. 2011;17(11):753-9.

Persistence with biologic therapies in the Medicare coverage gap. - PubMed - NCBI

Patterns of osteoporosis treatment change and treatment discontinuation among commercial and Medicare Advantage Prescription Drug members in a national health plan

Xu Y, Viswanathan HN, Ward MA, et al. Patterns of osteoporosis treatment change and treatment discontinuation among commercial and Medicare Advantage Prescription Drug in a national health plan. J Eval Clin Pract. 2013;19(1):50-9.

Patterns of osteoporosis treatment change and treatment discontinuation among commercial and Medicare Advantage Prescrip…

Out-of-pocket costs and prescription reversals: the case of oral linezolid

Pasquale MK, Louder AM, Deminski MC, Chambers RB, Haider S. Out-of-pocket costs and prescription reversals with oral linezolid. Am J Manag Care. 2013;19 (9):734-40.

Out-of-pocket costs and prescription reversals with oral linezolid. - PubMed - NCBI

http://apps.humana.com/marketing/documents.asp?file=2574273

Opioid-paracetamol prescription patterns and liver dysfunction: a retrospective cohort study in a population served by a US health benefits organization

Mort JR, Shiyanbola OO, Ndehi LN, Xu Y, Stacy JN. Opioid-paracetamol prescription patterns and liver dysfunction: a retrospective cohort study in a population served by a US health benefits organization. Drug Saf. 2011;34(11):1079-88.

Opioid-paracetamol prescription patterns and liver dysfunction: a retrospective cohort study in a population served by a…

Non-adherence to oral linezolid following hospitalization: a retrospective claims analysis of the incidence and consequence of claim reversals.

Ball AT, Xu Y, Sanchez RJ, Shelbaya A, Deminski MC, Nau DP. Non-adherence to oral linezolid following hospitalization: a retrospective claims analysis of the incidence and consequence of claim reversals. Clin Ther. 2010;32(13):2246-55.

Nonadherence to oral linezolid after hospitalization: a retrospective claims analysis of the incidence and consequence o…

Lessons from the leucovorin shortage between 2009 and 2012 in a Medicare Advantage population: where do we go from here?

Hayes MS, Ward MA, Slabaugh SL, Xu Y. Lessons from the leucovorin shortage between 2009 and 2012 in a Medicare Advantage population: where do we go from here? Am Drug Health Benefits. 2014;7(5):264-270.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4163778/

Intussusception risk after rotavirus vaccination in U.S. infants

Yih WK, Lieu TA, Kulldorff M, et al. Intussusception risk after rotavirus vaccination in U.S infants. N Engl J Med. 2014;370(6):503-12.

Intussusception risk after rotavirus vaccination in U.S. infants. - PubMed - NCBI

Impact of potential pregabalin or duloxetine drug-drug interactions on health care costs and utilization among Medicare members with fibromyalgia

Ellis JJ, Sadosky AB, Ten Eyck LL, et al. Impact of potential pregabalin or duloxetine drug-drug interactions on health care costs and utilization among Medicare members with fibromyalgia. Clinicoecon Outcomes Res. 2014;14(6):389-99.

Impact of potential pregabalin or duloxetine drug-drug interactions on health care costs and utilization among Medicare …

Impact of celecoxib restrictions in Medicare beneficiaries with arthritis

Louder AM, Joshi AV, Ball AT, Cappelleri JC, Deminski MC, Sanchez RJ. Impact of celecoxib restrictions in Medicare beneficiaries with arthritis. Am J Mang Care. 2011;17(7):503-12.

Impact of Celecoxib restrictions in medicare beneficiaries with arthritis. - PubMed - NCBI

Impact of a step-therapy protocol for pregabalin on healthcare utilization and expenditures in a commercial population.

Udall M, Louder A, Suehs BT, Cappelleri JC, Joshi AV, Patel NC. Impact of a step-therapy protocol for pregabalin on healthcare utilization and expenditures in a commercial population. J Med Econ. 2013;16(6):784-92.

Impact of a step-therapy protocol for pregabalin on healthcare utilization and expenditures in a commercial population. …

Impact of a pregabalin step therapy policy among Medicare Advantage beneficiaries

Suehs BT, Louder A, Udall M, Cappelleri JC, Joshi AV, Patel NC. Impact of a pregabalin step therapy policy among Medicare Advantage beneficiaries. Pain Pract. 2014;14(5):419-26.

Impact of a pregabalin step therapy policy among medicare advantage beneficiaries. - PubMed - NCBI

Cost drivers of prescription opioid abuse in commercial and Medicare populations

Pasquale MK, Joshi AV, Dufour R, et al. Cost drivers of prescription opioid abuse in commercial and Medicare populations. Pain Pract. 2014;14(3):16-25.

Cost drivers of prescription opioid abuse in commercial and Medicare populations. - PubMed - NCBI

Consumers’ misunderstanding of health insurance

Loewenstein G, Friedman JY, McGill B, et al. Consumers' misunderstanding of health insurance. J Health Econ. 2013;32(5):850-62.

Consumers' misunderstanding of health insurance. - PubMed - NCBI

Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs

Ward MA, Fang G, Richards KL, et al. Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs. Curr Med Res Opin. 2015;31(2):289-97.

Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors…

Cholesterol treatment patterns and cardiovascular clinical outcomes associated with colesevelam HCl and ezetimibe

Schwab P, Louder A, Li Y, Mallick R, Bays H. Cholesterol treatment patterns and cardiovascular clinical outcomes associated with colesevelam HCl and ezetimibe. Drugs Aging. 2014;31(9):683-94. doi: 10.1007/s40266-014-0200-6.

Cholesterol treatment patterns and cardiovascular clinical outcomes associated with colesevelam HCl and ezetimibe. - Pu…

Can claims-based data be used to recruit black and Hispanic subjects into clinical trials?

Palacio AM, Tamariz LJ, Uribe C, et al. Can claims-based data be used to recruit black and Hispanic subjects into clinical trials? Health Serv Res. 2012;47(2):770-82. doi:10.1111/j.1475-6773.2011.01316.x.

Can claims-based data be used to recruit black and Hispanic subjects into clinical trials? - PubMed - NCBI

Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study

Hazel-Fernandez L, Louder AM, Foster SA, Uribe CL, Burge RT. Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study. BMC Musculoskelet Discord. 2013;14(4). doi:10.1186/1471-2474-14-4.

Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients:…

Association of out-of-pocket pharmacy costs with adherence to varenicline

Suehs BT, Davis C, Galaznik A, Joshi AV, Zou KH, Patel NC. Association of out-of-pocket pharmacy costs with adherence to varenicline. J Manag Care Pharm. 2014;20(6):592-600.

Association of out-of-pocket pharmacy costs with adherence to varenicline. - PubMed - NCBI

Treatment interruption and regimen change in first-generation versus second-generation tyrosine kinase inhibitors used as first-line therapy for chronic myeloid leukemia

Ward MA, Fang G, Richards K, et al. Treatment interruption and regimen change in first-generation versus second-generation tyrosine kinase inhibitors used as first-line therapy for chronic myeloid leukemia. J Health Econ Outcomes Res. 2015;2(2):181-91.

Is response guided therapy being applied in the clinical setting? The hepatitis C example.

Harris JB, Ward MA, Schwab P. Is response guided therapy being applied in the clinical setting? The hepatitis C example. Am Drug Health Benefits. 2015;8(1):22-8.

Is response-guided therapy being applied in the clinical setting? The hepatitis C example. - PubMed - NCBI

Two randomized controlled pilot trials of social forces to improve statin adherence among patients with diabetes

Reese PP, Kessler JB, Doshi JA, et al. Two randomized controlled pilot trials of social forces to improve statin adherence among patients with diabetes. J Gen Intern Med. 2016;31(4):402-10.

http://www.ncbi.nlm.nih.gov/pubmed/26585957

Comparing two tyrosine kinase inhibitors for treatment of advanced renal cell carcinoma in Medicare and commercially insured patients

Racsa PN, Whisman TR, Worley K. Comparing two tyrosine kinase inhibitors for treatment of advanced renal cell carcinoma in Medicare and commercially insured patients. Curr Med Res Opin. 2015;31(10):1933-40.

http://www.ncbi.nlm.nih.gov/pubmed/26368665

Descriptive analysis of patients initiating regorafenib therapy in a large managed care population

Slabaugh L, Louder A, Michels SL, et al. Descriptive analysis of patients initiating regorafenib therapy in a large managed care population. Poster presentation at: International Society for Pharmacoeconomics and Outcomes Research 19th Annual International Meeting. May 31-June 4, 2014; Montreal, QC, Canada.

http://apps.humana.com/marketing/documents.asp?file=2573987

Using sequence discovery to target outreach for diabetes medication adherence

Lopez A, Long CL, Happe LE, Relish M. Using sequence discovery to target outreach for diabetes medication adherence. Am J Manag Care. 2015;21(11):e601-e608

Using sequence discovery to target outreach for diabetes medication adherence. - PubMed - NCBI

The impact of real world cardiovascular-related pharmacogenetic testing in an insured population

Billings J, Racsa PN, Bordenave K, Long CL, Ellis JJ. The impact of real world cardiovascular-related pharmacogenetic testing in an insured population. Int J Clin Pract. 2018 May 16:e13088. doi: 10.1111/ijcp.13088. [Epub ahead of print]

The impact of real-world cardiovascular-related pharmacogenetic testing in an insured population. - PubMed - NCBI

Diabetes therapeutic drug class: evaluating adherence and total cost of care

Runtas C, Bobbitt C, Burns S, Kendrick A, Dixon L, Lanham A. Diabetes therapeutic drug class: evaluating adherence and total cost of care. Poster presentation at: Pharmacy Quality Alliance Annual Meeting. May 16-18, 2018. Baltimore, MD.

http://apps.humana.com/marketing/documents.asp?file=3319823

Impact of a retrospective drug utilization review program on changing opioid prescribing behavior

Chiang J, Schwab P, McCulloch R, Brooks P, Rhodes C, Happe L. Impact of a retrospective drug utilization review program on changing opioid prescribing behavior. Poster presentation at: Academy of Managed Care and Specialty Pharmacy Annual Meeting. April 23-26, 2018. Boston, MA.

http://apps.humana.com/marketing/documents.asp?file=3319810

Characterizing Alzheimer’s disease in a Medicare Advantage population

Racsa P, Sehman M, Worley K, Ward MA, Ellis JJ. Characterizing Alzheimer’s disease in a Medicare Advantage population. Poster presentation at: 2018 Annual Scientific Meeting of the American Geriatrics Society. May 4, 2018. Orlando, FL.

Double threat: concurrent use of opioids and benzodiazepines

Pacholski EB, Weber JJ, Sandefur T, Cooley J, Gaddy RR. Double threat: Concurrent use of opioids and benzodiazepines. Poster presented at: Pharmacy Quality Alliance Annual Meeting. May 17-19, 2017. Baltimore, MD.

http://apps.humana.com/marketing/documents.asp?file=3288727

The effect of interactive reminders on medication adherence: A randomized trial.

Dai H, Mao D, Volpp KV, Pearce HE, Relish MJ, Lawnicki VF, Milkman K. The effect of interactive reminders on medication adherence: A randomized trial. Prev Med. 2017;103:98-102.

The effect of interactive reminders on medication adherence: A randomized trial. - PubMed - NCBI

Synchronized prescription refills and medication adherence: A retrospective claims analysis of Medicare patients on multiple maintenance medications

Doshi JA, Lim R, Li P, Young PP, Lawnicki VF, Troxel A, Volpp K. Synchronized prescription refills and medication adherence: A retrospective claims analysis of Medicare patients on multiple maintenance medications. Am J Manag Care. 2017;23(2):98-104.

Synchronized prescription refills and medication adherence: a retrospective claims analysis. - PubMed - NCBI

Impact of antidepressant medication adherence on health-related quality of life among older adults with newly diagnosed Major Depressive Disorder

Trevino L, Cordier T, Renda A, Gresky D, Ruble M. Impact of antidepressant medication adherence on health-related quality of life among older adults with newly diagnosed Major Depressive Disorder. Poster presentation at: American Psychiatric Association Annual Meeting. May 20-24, 2017. San Diego, CA.

http://apps.humana.com/marketing/documents.asp?file=3114657

Capitalizing on fresh starts does not impact the effectiveness of medication adherence reminders: a randomized trial

Dai H, Mao D, Riis J, Volpp KG, Relish MJ, Lawnicki VF, Milkman KL. Capitalizing on fresh starts does not impact the effectiveness of medication adherence reminders: a randomized trial. JAMA Cardiol. Published online February 8, 2017. doi:10.1001/jamacardio.2016.5794.

Effectiveness of Medication Adherence Reminders Tied to "Fresh Start" Dates: A Randomized Clinical Trial. - PubMed - NC…

Leveraging pharmacy retail clinic proximity and predictive models to reduce non-emergent emergency department utilization

Zhao Y, Schilling S, Johnson SK, Haugh G, Fan J, Singh H, Chui S, Gopal V. , Leveraging pharmacy retail clinic proximity and predictive models to reduce non-emergent emergency department utilization. Poster presentation at: American Pharmacists Association Annual Meeting & Exposition. March 24-27, 2017. San Francisco, CA.

http://apps.humana.com/marketing/documents.asp?file=3103555

Adherence, persistence, and healthcare costs for patients receiving dipeptidyl peptidase-4 inhibitors

Rascati K, Worley K, Meah Y, Everhart D. Adherence, persistence, and healthcare costs for patients receiving dipeptidyl peptidase-4 inhibitors. J Manage Care Pharm. 2017;23(3):299-306.

Adherence, Persistence, and Health Care Costs for Patients Receiving Dipeptidyl Peptidase-4 Inhibitors. - PubMed - NCBI

Successful implementation of a medication bundle for secondary prevention of cardiovascular outcomes among individuals with Medicare Advantage coverage

Morgan T, Das N, Megibben J, Gumpina R, Hyppolite-Oyadiran C, Simmons J, Hernandez, Y, Ryu J. Successful implementation of a medication bundle for secondary prevention of cardiovascular outcomes among individuals with Medicare Advantage coverage. Poster presentation at: AcademyHealth 9th Annual Conference on the Science of Dissemination and Implementation. December 14, 2016. Washington, DC.

http://apps.humana.com/marketing/documents.asp?file=3081065

Incidence, prevalence and treatment patterns of Alzheimer's disease and cognitive impairment-related conditions among 4.5 million members of a U.S. health plan

Ellis JJ, Nsiah I, Brown C, Murty C, Moore C, Beucker R, Esterly L, Saverno KR. Incidence, prevalence and treatment patterns of Alzheimer's disease and cognitive impairment-related conditions among 4.5 million members of a U.S. health plan. Poster presentation at: Academy of Managed Care Pharmacy Nexus 2016 Conference. October 4, 2016; National Harbor, MD.

http://apps.humana.com/marketing/documents.asp?file=3068091

PD-1 inhibitor prescribing patterns and utilization trends in a large national health plan

Ems D, Kennedy K, Gregory F, et al. PD-1 inhibitor prescribing patterns and utilization trends in a large national health plan. Poster presentation at: Academy of Managed Care Pharmacy Nexus 2016 Conference. October 4, 2016; National Harbor, MD.

http://apps.humana.com/marketing/documents.asp?file=3058757

Refill patterns with oral oncolytic medications

Dye JT, Murty S, Nsiah I, Kennedy K, Whisman T, Worley K. Refill patterns with oral oncolytic medications. J Clin Oncol. 2016;34(suppl; abstr e18216).

Refill patterns with oral oncolytic medications. | 2016 ASCO Annual Meeting | Abstracts | Meeting Library

Synchronized prescription refill program to improve medication adherence: a prospective study

Doshi JA, Lim R, Li P, Young PP, Lawnicki VF, State JJ, Troxel A, Volpp K. Synchronized prescription refill program to improve medication adherence: a prospective study. Health Affairs. 2016;35(8):1504-1512.

http://content.healthaffairs.org/content/35/8/1504.abstract

 

 

 

 

 

Does hepatitis C treatment adherence affect the risk of liver transplant? A historical cohort study

Ems E, Rasca P, Anderson C, Gregory F, Worley K, Brill J, Holt W. Does hepatitis C treatment adherence affect risk of liver transplantation? A historical cohort study. J Manag Care Pharm. 2016;22(7):863-71.

Does Hepatitis C Treatment Adherence Affect Risk of Liver Transplantation? A Historical Cohort Study. - PubMed - NCBI

Comparative effectiveness analysis of rapid-acting insulin therapies in a large national health plan

Rasca P, Meah Y, Ellis JJ, Saverno K. Comparative effectiveness analysis of rapid-acting insulin therapies in a large national health plan. J Manag Care Pharm. 2017:23(3):291-298.

https://www.ncbi.nlm.nih.gov/pubmed/?term=Comparative+effectiveness+of+rapid-acting+insulins+in+adults+with+diabete

Comparison of utilization and outcomes in patients with hemophilia receiving plasma-derived factors versus recombinant factors

Nsiah I, Aten A, Ellis J, Gregory F, Saverno, K. Comparison of utilization and outcomes in patients with hemophilia receiving plasma-derived factors versus recombinant factors. Poster presentation at: Academy of Managed Care & Specialty Pharmacy Annual Meeting. April 19-22, 2016; San Francisco, CA.

http://apps.humana.com/marketing/documents.asp?file=2859584

Antipsychotic prescribing patterns in a Medicare Advantage population of older individuals with dementia

Kester R, Unützer J, Hogan D, Huang H. Antipsychotic prescribing patterns in a Medicare Advantage population of older individuals with dementia. Poster presentation at: American Association for Geriatric Psychiatry Annual Meeting. March 17-20, 2016; Washington DC.

http://apps.humana.com/marketing/documents.asp?file=2882113

Impact of out-of-pocket costs on initial and subsequent prescription refills among new initiators of biologic therapies indicated for RA

Hopson S, Saverno K, Liu LZ, AL-Sabbagh A, Orazem J, Pasquale MK. Impact of out-of-pocket costs on initial and subsequent prescription refills among new initiators of biologic therapies indicated for RA. JMCP 2016; 22(2):122-130.

Use of add-on treatment to metformin monotherapy for patients with type 2 diabetes and suboptimal glycemic control: a U.S. database study

Yu S, Schwab P, Bian B, Radican L, Tuncelli K. Use of add-on treatment to metformin monotherapy for patients with type 2 diabetes and suboptimal glycemic control: a U.S. database study. J Manag Care Spec Pharm. 2016;22(3):272-80.

http://www.jmcp.org/doi/pdf/10.18553/jmcp.2016.22.3.272

Patterns of care in patients with metastatic renal cell carcinoma among a US payer population

Miller LA, Stemkowski S, Saverno K, Lane D, Tao Z, Hackshaw M, Loy B. Patterns of care in patients with metastatic renal cell carcinoma among a US payer population. J Manag Care Spec Pharm, 2016;22(3):219-226

http://www.jmcp.org/doi/pdf/10.18553/jmcp.2016.22.3.219

Evaluation of molecular testing patterns in metastatic non-small cell lung cancer at a large US health plan

MacLean EA, Louder AM, Saverno KR, Smith G, Mardekian J, Bruins C, Ward M, Sweetman RW, Pasquale M. Evaluation of molecular testing patterns in metastatic non-small cell lung cancer at a large US health plan. American Journal of Managed Care 2016; 22(2): e60-e67.

Evaluation of molecular testing patterns in metastatic non-small cell lung cancer at a large U.S. health plan. | 2014 AS…

Early treatment revisions by addition or switch for type 2 diabetes: impact on glycemic control, diabetic complications, and healthcare costs

Schwab P, Saundankar V, Bouchard J, Wintfeld N, Suehs B, Moretz C, Allen E, DeLuzio A. Early treatment revisions by addition or switch for type 2 diabetes: impact on glycemic control, diabetic complications, and healthcare costs. BMJ Open Diabetes Research and Care 2016;4:e000099. doi:10.1136/bmjdrc-2015-000099

Early treatment revisions by addition or switch for type 2 diabetes: impact on glycemic control, diabetic complications,…

COPD exacerbations associated with the modified medical research council scale and COPD assessment test among Humana’s medicare members

Pasquale MK, Xu Y, Baker CL, Zou KH, Teeter JG, Renda AM, Davis CC, Lee TC, Bobula J. COPD exacerbations associated with the modified medical research council scale and COPD assessment test among Humana’s medicare members. International Journal of COPD 2016; 11:111-121.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716734/pdf/copd-11-111.pdf

Effect of new drug therapies on current metastatic melanoma treatment patterns

Kennedy K, Murty S, Dye J, Whisman T, Worley K. Effect of new drug therapies on current metastatic melanoma treatment patterns. J Natl Compr Canc Netw. 2016;14(5.5):e1-e30.

http://apps.humana.com/marketing/documents.asp?file=2852434

Trusted third party influencers for medication adherence

Relish M, Young P, Vogel V, et al. Trusted third party influencers for medication adherence. Circ Cardiovasc Qual Outcomes. 2016;9(Suppl 2):A266.

http://apps.humana.com/marketing/documents.asp?file=2834104

Validation of febrile seizures identified in the mini-sentinel post-licensure rapid immunization safety monitoring (PRISM) system

Kawai AT, Martin D, McMahill-Walraven CN, et al. Validation of febrile seizures identified in the mini-sentinel post-licensure rapid immunization safety monitoring (PRISM) system. Poster presentation at: Infectious Disease Week. October 8-14, 2014; Philadelphia, PA.

http://apps.humana.com/marketing/documents.asp?file=2574559

Utilization of paliperidone long-acting injection among Medicare Advantage and Medicare Prescription Drug Plan members

Suehs B, Li Y, Howe A, et al. Utilization of paliperidone long-acting injection among Medicare Advantage and Medicare Prescription Drug Plan members. Poster presentation at: International Society for Pharmacoeconomics and Outcomes Research 17th Annual International Meeting. June 2-6, 2012; Washington, DC.

http://apps.humana.com/marketing/documents.asp?file=2574546

Understanding patient preferences associated with the use of biologic therapies for RA: results of a conjoint analysis

Louder A, Saverno K, Singh A. et al. Understanding patient preferences associated with the use of biologic therapies for RA: results of a conjoint analysis. Poster presentation at: American College of Rheumatology Annual Meeting. November 14-19, 2014; Boston, MA.

http://apps.humana.com/marketing/documents.asp?file=2542995

Retrospective cohort analysis of the patterns and predictors of metformin treatment change in a Medicare Advantage patient population from a large national health plan

Hazel-Fernandez L, Xu Y, Moretz C, et al. Retrospective cohort analysis of the patterns and predictors of metformin treatment change in a Medicare Advantage patient population from a large national health plan. Poster presentation at: International Society for Pharmacoeconomics and Outcomes Research 19th Annual International Meeting. May 31-June 4, 2014; Montreal, QC, Canada.

http://apps.humana.com/marketing/documents.asp?file=2574507

Relative adherence across sites of care for infliximab patients with Crohn's disease

Michels SL, Eyck T, Vanderpoel J, et al. Relative adherence across sites of care for infliximab patients with Crohn's disease. Poster presentation at: International Society for Pharmacoeconomics and Outcomes Research 19th Annual International Meeting. May 31-June 4, 2014; Montreal, QC, Canada.

http://apps.humana.com/marketing/documents.asp?file=2574494

Potential drug-drug interactions and opioid use among painful diabetic peripheral neuropathy Medicare members newly started on pregabalin or duloxetine

Eyck LT, Sadosky A, Ellis J, et al. Potential drug-drug interactions and opioid use among painful diabetics peripheral neuropathy Medicare members newly started on pregablin or duloxetine. Poster presentation at: American Diabetes Association 74th Scientific Sessions. June 13-17, 2014; San Francisco, CA.

http://apps.humana.com/marketing/documents.asp?file=2574325

Patterns of lubiprostone utilization in a large managed care population

Sussman D, Tamariz L, Droege M, Harkins T, et al. Patterns of lubiprostone utilization in a large managed care population. Poster presentation at: Digestive Disease Week. May 1-5, 2010; New Orleans, LA.

http://apps.humana.com/marketing/documents.asp?file=2574312

Patterns of lubiprostone use and costs in a large health benefits company

Sussman D, Tamariz L, Droege M, Harkins T, et al. Patterns of lubiprostone use and costs in a large health benefits company. Poster presentation at: International Society for Pharmacoeconomics and Outcomes Research 15th Annual International Meeting. May 15-19, 2010; Atlanta, GA.

http://apps.humana.com/marketing/documents.asp?file=2574286

Out-of-pocket costs and prescription reversals: the case of oral linezolid

Pasquale M, Louder AM, Deminski MC, et al. Out-of-pocket costs and prescription reversals: the case of oral linezolid. Poster presentation at: Academy of Managed Care Pharmacy 25th Annual Meeting and Expo. April 2-5, 2013; San Diego, CA

http://apps.humana.com/marketing/documents.asp?file=2574273

Opportunities and challenges in providing face-to-face and telephonic MTM services to a commercially-insured population

Crawford S, Touchette DR, Sharp LK, et al. Opportunities and challenges in providing face-to-face and telephonic MTM services to a commercially-insured population. Poster presentation at: Academy of Managed Care Pharmacy Nexus. October 7-10, 2014; Boston, MA.

http://apps.humana.com/marketing/documents.asp?file=2645188

Impact of roflumilast on COPD exacerbations, healthcare utilization and costs in a Medicare Advantage population

Ellis J, Sun SX, Moll K, et al. Impact of roflumilast on COPD exacerbations, healthcare utilization and costs in a Medicare Advantage population. Poster presentation at: American Thoracic Society International Conference. May 16-21, 2014; San Diego, CA.

http://apps.humana.com/marketing/documents.asp?file=2574234

Impact of patient behaviors and attitudes on teriparatide adherence in a Medicare Part D population

Hazel-Fernandez L, Foater SA, Uribe C, et al. Impact of patient behaviors and attitudes on teriparatide adherence in a Medicare Part D population. Poster presentation at: International Society for Pharmacoeconomics and Outcomes Research 16th Annual International Meeting. May 21-25, 2011; Baltimore, MD.

http://apps.humana.com/marketing/documents.asp?file=2574221

Impact of a step-therapy policy restriction for pregabalin on health care utilization and expenditures in a commercial population

Louder A, Udall M, Suehs BT, et al. Impact of a step-therapy policy restriction for pregabalin on health care utilization and expenditures in a commercial population. Poster presentation at: Academy of Managed Care Pharmacy Educational Conference. October 3-5, 2012; Cincinnati, OH.

http://apps.humana.com/marketing/documents.asp?file=2574208

Identifying schizophrenia patients at high-risk for antipsychotic nonadherence using the assessment for quality improvement and risk evaluation tool

Muser E, Slabaugh SL, Louder A, Patel N. Identifying schizophrenia patients at high-risk for antipsychotic nonadherence using the assessment for quality improvement and risk evaluation tool. Poster presentation at: International Society for Pharmacoeconomics and Outcomes Research 18th Annual International Meeting. May 18-22, 2013; New Orleans, LA.

http://apps.humana.com/marketing/documents.asp?file=2574195

Healthcare costs by level of adherence for infliximab patients with Crohn's disease

Michels SL, Eyck T, Vanderpoel J, et al. Healthcare costs by level of adherence for infliximab patients with Crohn's disease. Poster presentation at: International Society for Pharmacoeconomics and Outcomes Research 19th Annual International Meeting. May 31-June 4, 2014; Montreal, QC, Canada.

http://apps.humana.com/marketing/documents.asp?file=2573974

Delayed treatment modifications for patients with type 2 diabetes mellitus (T2DM) with very poor glycemic control

Schwab P, Saundankar V, Bouchard J, et al. Delayed treatment modifications for patients with type 2 diabetes mellitus (T2DM) with very poor glycemic control. Poster presentation at: International Society for Pharmacoeconomics and Outcomes Research 19th Annual International Meeting. May 31-June 4, 2014; Montreal, QC, Canada.

http://apps.humana.com/marketing/documents.asp?file=2345278

Concomitant statin use with ezetimibe or colesevelam for treatment of hypercholesterolemia

Ye X, Bays H, Schwab P, et al. Concomitant statin use with ezetimibe or colesevelam for treatment of hypercholesterolemia. Poster presentation at: International Society for Pharmacoeconomics and Outcomes Research 18th Annual International Meeting. May 18-22, 2013; New Orleans, LA.

http://apps.humana.com/marketing/documents.asp?file=2573922

Comparative outcomes of patients newly initiating first-generation vs. second-generation tyrosine kinase inhibitors for chronic myeloid leukemia

Ward MA, Fang G, Richards K, et al. Comparative outcomes of patients newly initiating first-generation vs. second-generation tyrosine kinase inhibitors for chronic myeloid leukemia. Poster presentation at: Academy of Managed Care Pharmacy Nexus. October 7-10, 2014; Boston, MA.

http://apps.humana.com/marketing/documents.asp?file=2452333

Comorbidity burden, health care resource utilization, and health care cost among Medicare Advantage members with Alzheimer's disease

Suehs B, Davis CD, Shah SN, et al. Comorbidity burden, health care resource utilization, and health care cost among Medicare Advantage members with Alzheimer's disease. Poster presentation at: Academy of Managed Care Pharmacy Educational Conference. October 3-5, 2012; Cincinnati, OH.

http://apps.humana.com/marketing/documents.asp?file=2573909

Clinical and economic outcomes associated with teriparatide adherence in Medicare Part D recipients: a retrospective cohort study

Hazel-Fernandez L, Louder AM, Foater SA, et al. Clinical and economic outcomes associated with teriparatide adherence in Medicare Part D recipients: a retrospective cohort study. Poster presentation at: International Society for Pharmacoeconomics and Outcomes Research 17th Annual International Meeting. June 2-6, 2012; Washington, DC.

http://apps.humana.com/marketing/documents.asp?file=2573896

Claims-based algorithm targeting Medicare Advantage Prescription Drug (MAPD) members with chronic obstructive pulmonary disease (COPD) for care intervention

Worley K, Shenolikar R, Song F, et al.  Claims-based algorithm targeting Medicare Advantage Prescription Drug (MAPD) members with chronic obstructive pulmonary disease (COPD) for care intervention. Poster presentation at: American Society of Health Systems Pharmacists Midyear Clinical Meeting; December 4-8, 2011; New Orleans, LA.

http://apps.humana.com/marketing/documents.asp?file=2573883

Anticoagulation treatment in high risk Medicare Advantage patients with non-valvular atrial fibrillation

Dye J, Louder A, Pasquale M. Anticoagulation treatment in high risk Medicare Advantage patients with non-valvular atrial fibrillation. Poster presentation at: American Heart Association Scientific Sessions. November 15-19, 2014; Chicago, IL.

http://apps.humana.com/marketing/documents.asp?file=2573844

Analysis of first dose observation data for MS treatment with fingolimod (DX14)

Schwab P, Zhou Y, Stemkowski S, et al. Analysis of first dose observation data for MS treatment with fingolimod. Poster presentation at: The Consortium for Multiple Sclerosis Centers and Americas Committee for Treatment and Research in Multiple Sclerosis 5th Cooperative Meeting. May 30-June 2, 2012; San Diego, CA.

http://apps.humana.com/marketing/documents.asp?file=2645149

All-cause and driver-specific healthcare resource utilization in newly diagnosed non-valvular atrial fibrillation patients newly initiating dabigatran and warfarin

Michels SL, Sheer R, Ghate SR, Moretz C, Wang C, Stemkowski S, Sander SD, Andrews G. All-cause and driver-specific healthcare resource utilization in newly diagnosed non-valvular atrial fibrillation patients newly initiating dabigatran and warfarin. Poster presentation at: Academy of Managed Care Pharmacy 26th Annual Meeting & Expo. April 1-4, 2014; Tampa, FL.

http://apps.humana.com/marketing/documents.asp?file=2332018

A retrospective cohort study to identify Medicare members at risk of low adherence to glaucoma medication

Sheer R, Bunniran S, Uribe C. A retrospective cohort study to identify Medicare members at risk of low adherence to glaucoma medication. Poster presentation at: Academy of Managed Care Pharmacy Nexus. October 7-10, 2014; Boston, MA.

http://apps.humana.com/marketing/documents.asp?file=2645136

Risk of liver transplant in treated vs. untreated hepatitis C

Ems D, Racsa P, Anderson C, Gregory F, Worley K. Risk of liver transplant in treated vs. untreated hepatitis C. Poster presentation at: International Society for Pharmacoeconomics and Outcomes Research 20th Annual International Meeting. May18-20, 2015; Philadelphia, PA.

https://apps.humana.com/marketing/documents.asp?file=2637778

Prescribing practices of antidepressant medications for treatment of major depressive disorder (MDD) among insured members (n=68,394)

Treviño LA, Treviño K,  Racsa P,  Biggan JR,  Gresky D, Gopal V. Prescribing practices of antidepressant medications for treatment of major depressive disorder (MDD) among insured members (n=68,394). Poster presentation at: American Psychiatric Association 168th Annual Meeting. May 16-20, 2015; Toronto, ON, Canada.

http://apps.humana.com/marketing/documents.asp?file=2640079

Comparing costs and health outcomes in initial therapy with sunitinib versus pazopanib for renal cell carcinoma

Racsa P, Worley K, Whisman T. Comparing costs and health outcomes in initial therapy with sunitinib versus pazopanib for renal cell carcinoma. J Natl Compr Canc Netw. 2015;13:625-26.

https://apps.humana.com/marketing/documents.asp?file=2584023

An examination of influenza vaccination timing and risk of infection

Glasheen W, Renda A. An examination of influenza vaccination timing and risk of infection. Poster presentation at: Preventative Medicine 2015. February25-28, 2015; Atlanta, GA.

http://apps.humana.com/marketing/documents.asp?file=2583061

Podcast: https://www.brainshark.com/humana/fluvaccine

Treatment rates and prevalence of high priority comorbidities for treatment initiation in people with hepatitis C

Racsa P, Ems D, Anderson C, Gregory F, Worley K. Treatment rates and prevalence of high priority comorbidities for treatment initiation in people with hepatitis C. Poster presentation at: AcademyHealth Annual Research Meeting. June 14-16, 2015; Minneapolis, MN.

http://apps.humana.com/marketing/documents.asp?file=2645240

Prescribing practices of antidepressant medications for treatment of major depressive disorder (MDD) among insured members (n=68,394)

Treviño LA, Treviño K, Racsa P, Biggan JR, Gresky D, Gopal V. Prescribing practices of antidepressant medications for treatment of major depressive disorder (MDD) among insured members (n=68,394). Poster (encore) presentation at: American Psychiatric Association Institute on Psychiatric Services, The Mental Health Services Conference.  October 8-11, 2015; New York, NY.

http://apps.humana.com/marketing/documents.asp?file=2771561

Characteristics of and medication adherence for diabetic patients receiving dipeptidyl peptidase-4 inhibitors in the US Medicare and commercial insurance plans

Rascati K, Worley K, Meah Y, Everhart D. Characteristics of and medication adherence for diabetic patients receiving dipeptidyl peptidase-4 inhibitors in the US Medicare and commercial insurance plans. Poster presentation at: Academy of Managed Care Pharmacy Nexus Conference. October 26-29, 2015; Orlando, FL.

http://apps.humana.com/marketing/documents.asp?file=2799836

2014 trends in the Medicare Part D coverage gap

Mitchell B, Preston N, Relish M. 2014 trends in the Medicare Part D coverage gap. Poster presentation at: Academy of Managed Care Pharmacy Nexus conference. October 26-29, 2015; Orlando, FL.

http://apps.humana.com/marketing/documents.asp?file=2803008

Costs for diabetic patients receiving dipeptidyl peptidase-4 (DPP-4) inhibitors in US Medicare and commercial insurance plans

Rascati KL, Worley K, Everhart D, Meah Y. Costs for diabetic patients receiving dipeptidyl peptidase-4 (DPP-4) inhibitors in US Medicare and commercial insurance plans. Poster presentation at: International Society for Pharmacoeconomics and Outcomes Research 18th Annual European Congress. November 7-11, 2015; Milan, Italy.

http://apps.humana.com/marketing/documents.asp?file=2819232

Do people who are adherent to their medications have fewer unhealthy days?

Cordier T, Slabuagh SL, Young P, Havens, E, Goapl V, Prewitt T. Do people who are adherent to their medications have fewer unhealthy days? Podium presentation at: Preventive Medicine. February 27, 2016; Washington DC.

http://apps.humana.com/marketing/documents.asp?file=2838862

Association between osteoporosis treatment change and total direct healthcare costs in Medicare Advantage Prescription Drug (MAPD) plan

Ward M.  Association between osteoporosis treatment change and total direct healthcare costs in Medicare Advantage Prescription Drug (MAPD) plan. Podium presentation at: Academy of Managed Care Pharmacy Educational Conference. October, 2011; Atlanta, GA.

Associations between osteoporosis treatment change, adherence, and incident fractures among members in a Medicare Advantage Prescription Drug (MAPD) plan

Xu Y.  Associations between osteoporosis treatment change, adherence, and incident fractures among members in a Medicare Advantage Prescription Drug (MAPD) plan. Podium presentation at: American Society for Bone and Mineral Research. September, 2011; San Diego, CA.

Bridging the gap: impact of Part D low income subsidy coverage or branded gap coverage on medication continuity among osteoporosis patients treated with teriparatide

Uribe C.  Bridging the gap: impact of Part D low income subsidy coverage or branded gap coverage on medication continuity among osteoporosis patients treated with teriparatide. Podium presentation at: AcademyHealth. June, 2009; Chicago, IL.

Electronically-transmitted prescriptions involved in primary prescription abandonment

Ellis J.  Electronically-transmitted prescriptions involved in primary prescription abandonment. Podium presentation at: Academy of Managed Care Pharmacy Nexus Meeting. October, 2014; Boston, MA.

Evaluating allopurinol therapy and serum uric acid (sUA) levels in Medicare beneficiaries with gout

Ward M.  Evaluating allopurinol therapy and serum uric acid (sUA) levels in Medicare beneficiaries with gout. Podium presentation at: American Geriatrics Society. May, 2012; Seattle, WA.

Evaluating characteristics of electronic prescriptions using pharmacy claims data

Slabaugh S. Evaluating characteristics of electronic prescriptions using pharmacy claims data.  Podium presentation at: Academy of Managed Care’s Annual Meeting & Showcase. April, 2012; San Francisco, CA.

Evaluating primary adherence using electronic prescription transactions

Constantino M.  Evaluating primary adherence using electronic prescription transactions. Podium presentation at: Academy of Managed Care Pharmacy Annual Meeting. April, 2011; Minneapolis, MN.

Evaluation of narcotic/acetaminophen prescription patterns and acetaminophen toxicity in a managed care population

Xu Y. Evaluation of narcotic/acetaminophen prescription patterns and acetaminophen toxicity in a managed care population. Podium presentation at: Academy of Managed Care Pharmacy Annual Meeting. April, 2010; San Diego, CA.

Evaluation of PQA draft measures of MTM performance

Ward M.  Evaluation of PQA draft measures of MTM performance. Podium presentation at: Academy of Managed Care Pharmacy Annual Meeting. April, 2011; Minneapolis, MN.

Evaluation of the impact of consumer messaging on medication treatment patterns

Louder A.  Evaluation of the impact of consumer messaging on medication treatment patterns. Podium presentation at: Academy of Managed Care Pharmacy Annual Meeting. April, 2010; San Diego, CA.

Impact of celecoxib restrictions in Medicare beneficiaries with arthritis

Louder A.  Impact of celecoxib restrictions in Medicare beneficiaries with arthritis. Podium presentation at: Academy of Managed Care Pharmacy Educational Conference. October, 2010. St. Louis, MO.

Impact of generic conversion on cardiovascular medication adherence: a retrospective analysis in a managed care database

Ward M. Impact of generic conversion on cardiovascular medication adherence: a retrospective analysis in a managed care database. Podium presentation at: Academy of Managed Care Pharmacy Annual Meeting & Showcase. April, 2008; San Francisco, CA.

Impact of medication therapy management on formulary tier changes in a commercial population

Ward M. Impact of medication therapy management on formulary tier changes in a commercial population. Podium presentation at: Academy of Managed Care Pharmacy Educational Conference. October, 2008; Kansas City, Kansas.

Impact of out-of-pocket costs on initial and subsequent prescription refills among new initiators of biologic therapies indicated for RA

Saverno K, Pasquale M. Impact of out-of-pocket costs on initial and subsequent prescription refills among new initiators of biologic therapies indicated for RA. Oral presentation presented at: Academy of Managed Care Pharmacy. October, 2014; Boston, MA.

http://www.jmcp.org/doi/pdf/10.18553/jmcp.2016.14261

Impact of the Affordable Care Act on medication adherence in a population of Medicare Part D beneficiaries

Ward M.  Impact of the Affordable Care Act on medication adherence in a population of Medicare Part D beneficiaries. Oral presentation presented at: Academy of Managed Care Pharmacy Annual Meeting & Showcase. April, 2012; San Francisco, CA.

Patterns of osteoporosis treatment change in a Medicare Advantage prescription drug (MAPD) plan

Xu Y. Patterns of osteoporosis treatment change in a Medicare Advantage Prescription Drug (MAPD) plan. Oral presentation presented at: Academy of Managed Care Pharmacy Annual Meeting & Showcase. April, 2011;  Minneapolis, MN.

Pharmacologic management of bipolar disorder in a Medicare Advantage population

Huang H, Gören JL, Chan YF, et al. Pharmacologic management of bipolar disorder in a Medicare Advantage population. Psychosomatics. 2014;55(6):572-7.

Pharmacologic management of bipolar disorder in a Medicare Advantage population. - PubMed - NCBI

Depression care and treatment in a chronically ill Medicare population

Huang H, Russo J, Bauer AM, et al. Depression care and treatment in a chronically ill Medicare population. Gen Hosp Psychiatry. 2013;35(4):382-6.

Depression care and treatment in a chronically ill Medicare population. - PubMed - NCBI

Validity of diagnostic codes to identify cases of severe acute liver injury in the U.S. Food and Drug Administration's Mini-Sentinel Distributed Database

Lo Re V 3rd, Haynes K, Goldberg D, et al. Validity of diagnostic codes to identify cases of severe acute liver injury in the US Food and Drug Administration's Mini-Sentinel Distributed Database. Pharmacoepidemiol Drug Saf. 2013;22(8):861-72.

http://www.ncbi.nlm.nih.gov/pubmed/23801638

Validation of anaphylaxis in the Food and Drug Administration’s Mini-Sentinel

Walsh KE, Cutrona SL, Foy S, et al. Validation of anaphylaxis in the Food and Drug Administration's Mini-Sentinel. Pharmacoepidemiol Drug Saf. 2013;22(11):1205-13.

Validation of anaphylaxis in the Food and Drug Administration's Mini-Sentinel. - PubMed - NCBI

The prevalence of diagnosed opioid abuse in commercial and Medicare managed care populations

Dufour R, Joshi AV, Pasquale MK, et al. The prevalence of diagnosed opioid abuse in commercial and Medicare managed care populations. Pain Pract. 2014;14(3):E106-15.

The prevalence of diagnosed opioid abuse in commercial and Medicare managed care populations. - PubMed - NCBI

The organizational structure and governing principles of the Food and Drug Administration's Mini-Sentinel pilot program

Forrow S, Campion DM, Herrinton LJ, et al. The organizational structure and governing principles of the Food and Drug Administration's Mini-Sentinel pilot program. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):12-7.

The organizational structure and governing principles of the Food and Drug Administration's Mini-Sentinel pilot program.…

Risk for fractures with centrally acting muscle relaxants: an analysis of a national Medicare Advantage claims database

Golden AG, Ma Q, Nair V, Florez HJ, Roos BA. Risk for fractures with centrally acting muscle relaxants: an analysis of a national Medicare Advantage claims database. Ann Pharmacother. 2010;44(9):1369-75.

Risk for fractures with centrally acting muscle relaxants: an analysis of a national Medicare Advantage claims database.…

Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage prescription drug plan population

Bergeson JG, Worley K, Louder A, Ward M, Graham J. Retrospective database analysis of the impact of prior authorization for Type 2 Diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population. J Manag Care Pharm.2013;19(5):374-84.

Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care cost…

Pharmacist-provided telephonic medication therapy management in an MAPD plan

Ward MA, Xu Y. Pharmacist-provided telephonic medication therapy management in an MAPD plan. Am J Manag Care. 2011;17(10):e399-409.

Pharmacist-provided telephonic medication therapy management in an MAPD plan. - PubMed - NCBI

Persistence with biologic therapies in the Medicare coverage gap

Tamariz L, Uribe CL, Luo J, et al. Persistence with biologic therapies in the Medicare coverage gap. Am J Manag Care. 2011;17(11):753-9.

Persistence with biologic therapies in the Medicare coverage gap. - PubMed - NCBI

Patterns of osteoporosis treatment change and treatment discontinuation among commercial and Medicare Advantage Prescription Drug members in a national health plan

Xu Y, Viswanathan HN, Ward MA, et al. Patterns of osteoporosis treatment change and treatment discontinuation among commercial and Medicare Advantage Prescription Drug in a national health plan. J Eval Clin Pract. 2013;19(1):50-9.

Patterns of osteoporosis treatment change and treatment discontinuation among commercial and Medicare Advantage Prescrip…

Out-of-pocket costs and prescription reversals: the case of oral linezolid

Pasquale MK, Louder AM, Deminski MC, Chambers RB, Haider S. Out-of-pocket costs and prescription reversals with oral linezolid. Am J Manag Care. 2013;19 (9):734-40.

Out-of-pocket costs and prescription reversals with oral linezolid. - PubMed - NCBI

http://apps.humana.com/marketing/documents.asp?file=2574273

Opioid-paracetamol prescription patterns and liver dysfunction: a retrospective cohort study in a population served by a US health benefits organization

Mort JR, Shiyanbola OO, Ndehi LN, Xu Y, Stacy JN. Opioid-paracetamol prescription patterns and liver dysfunction: a retrospective cohort study in a population served by a US health benefits organization. Drug Saf. 2011;34(11):1079-88.

Opioid-paracetamol prescription patterns and liver dysfunction: a retrospective cohort study in a population served by a…

Non-adherence to oral linezolid following hospitalization: a retrospective claims analysis of the incidence and consequence of claim reversals.

Ball AT, Xu Y, Sanchez RJ, Shelbaya A, Deminski MC, Nau DP. Non-adherence to oral linezolid following hospitalization: a retrospective claims analysis of the incidence and consequence of claim reversals. Clin Ther. 2010;32(13):2246-55.

Nonadherence to oral linezolid after hospitalization: a retrospective claims analysis of the incidence and consequence o…

Lessons from the leucovorin shortage between 2009 and 2012 in a Medicare Advantage population: where do we go from here?

Hayes MS, Ward MA, Slabaugh SL, Xu Y. Lessons from the leucovorin shortage between 2009 and 2012 in a Medicare Advantage population: where do we go from here? Am Drug Health Benefits. 2014;7(5):264-270.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4163778/

Intussusception risk after rotavirus vaccination in U.S. infants

Yih WK, Lieu TA, Kulldorff M, et al. Intussusception risk after rotavirus vaccination in U.S infants. N Engl J Med. 2014;370(6):503-12.

Intussusception risk after rotavirus vaccination in U.S. infants. - PubMed - NCBI

Impact of potential pregabalin or duloxetine drug-drug interactions on health care costs and utilization among Medicare members with fibromyalgia

Ellis JJ, Sadosky AB, Ten Eyck LL, et al. Impact of potential pregabalin or duloxetine drug-drug interactions on health care costs and utilization among Medicare members with fibromyalgia. Clinicoecon Outcomes Res. 2014;14(6):389-99.

Impact of potential pregabalin or duloxetine drug-drug interactions on health care costs and utilization among Medicare …

Impact of celecoxib restrictions in Medicare beneficiaries with arthritis

Louder AM, Joshi AV, Ball AT, Cappelleri JC, Deminski MC, Sanchez RJ. Impact of celecoxib restrictions in Medicare beneficiaries with arthritis. Am J Mang Care. 2011;17(7):503-12.

Impact of Celecoxib restrictions in medicare beneficiaries with arthritis. - PubMed - NCBI

Impact of a step-therapy protocol for pregabalin on healthcare utilization and expenditures in a commercial population.

Udall M, Louder A, Suehs BT, Cappelleri JC, Joshi AV, Patel NC. Impact of a step-therapy protocol for pregabalin on healthcare utilization and expenditures in a commercial population. J Med Econ. 2013;16(6):784-92.

Impact of a step-therapy protocol for pregabalin on healthcare utilization and expenditures in a commercial population. …

Impact of a pregabalin step therapy policy among Medicare Advantage beneficiaries

Suehs BT, Louder A, Udall M, Cappelleri JC, Joshi AV, Patel NC. Impact of a pregabalin step therapy policy among Medicare Advantage beneficiaries. Pain Pract. 2014;14(5):419-26.

Impact of a pregabalin step therapy policy among medicare advantage beneficiaries. - PubMed - NCBI

Cost drivers of prescription opioid abuse in commercial and Medicare populations

Pasquale MK, Joshi AV, Dufour R, et al. Cost drivers of prescription opioid abuse in commercial and Medicare populations. Pain Pract. 2014;14(3):16-25.

Cost drivers of prescription opioid abuse in commercial and Medicare populations. - PubMed - NCBI

Consumers’ misunderstanding of health insurance

Loewenstein G, Friedman JY, McGill B, et al. Consumers' misunderstanding of health insurance. J Health Econ. 2013;32(5):850-62.

Consumers' misunderstanding of health insurance. - PubMed - NCBI

Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs

Ward MA, Fang G, Richards KL, et al. Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs. Curr Med Res Opin. 2015;31(2):289-97.

Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors…

Cholesterol treatment patterns and cardiovascular clinical outcomes associated with colesevelam HCl and ezetimibe

Schwab P, Louder A, Li Y, Mallick R, Bays H. Cholesterol treatment patterns and cardiovascular clinical outcomes associated with colesevelam HCl and ezetimibe. Drugs Aging. 2014;31(9):683-94. doi: 10.1007/s40266-014-0200-6.

Cholesterol treatment patterns and cardiovascular clinical outcomes associated with colesevelam HCl and ezetimibe. - Pu…

Can claims-based data be used to recruit black and Hispanic subjects into clinical trials?

Palacio AM, Tamariz LJ, Uribe C, et al. Can claims-based data be used to recruit black and Hispanic subjects into clinical trials? Health Serv Res. 2012;47(2):770-82. doi:10.1111/j.1475-6773.2011.01316.x.

Can claims-based data be used to recruit black and Hispanic subjects into clinical trials? - PubMed - NCBI

Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study

Hazel-Fernandez L, Louder AM, Foster SA, Uribe CL, Burge RT. Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study. BMC Musculoskelet Discord. 2013;14(4). doi:10.1186/1471-2474-14-4.

Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients:…

Association of out-of-pocket pharmacy costs with adherence to varenicline

Suehs BT, Davis C, Galaznik A, Joshi AV, Zou KH, Patel NC. Association of out-of-pocket pharmacy costs with adherence to varenicline. J Manag Care Pharm. 2014;20(6):592-600.

Association of out-of-pocket pharmacy costs with adherence to varenicline. - PubMed - NCBI

Treatment interruption and regimen change in first-generation versus second-generation tyrosine kinase inhibitors used as first-line therapy for chronic myeloid leukemia

Ward MA, Fang G, Richards K, et al. Treatment interruption and regimen change in first-generation versus second-generation tyrosine kinase inhibitors used as first-line therapy for chronic myeloid leukemia. J Health Econ Outcomes Res. 2015;2(2):181-91.

Is response guided therapy being applied in the clinical setting? The hepatitis C example.

Harris JB, Ward MA, Schwab P. Is response guided therapy being applied in the clinical setting? The hepatitis C example. Am Drug Health Benefits. 2015;8(1):22-8.

Is response-guided therapy being applied in the clinical setting? The hepatitis C example. - PubMed - NCBI

Two randomized controlled pilot trials of social forces to improve statin adherence among patients with diabetes

Reese PP, Kessler JB, Doshi JA, et al. Two randomized controlled pilot trials of social forces to improve statin adherence among patients with diabetes. J Gen Intern Med. 2016;31(4):402-10.

http://www.ncbi.nlm.nih.gov/pubmed/26585957

Comparing two tyrosine kinase inhibitors for treatment of advanced renal cell carcinoma in Medicare and commercially insured patients

Racsa PN, Whisman TR, Worley K. Comparing two tyrosine kinase inhibitors for treatment of advanced renal cell carcinoma in Medicare and commercially insured patients. Curr Med Res Opin. 2015;31(10):1933-40.

http://www.ncbi.nlm.nih.gov/pubmed/26368665

Descriptive analysis of patients initiating regorafenib therapy in a large managed care population

Slabaugh L, Louder A, Michels SL, et al. Descriptive analysis of patients initiating regorafenib therapy in a large managed care population. Poster presentation at: International Society for Pharmacoeconomics and Outcomes Research 19th Annual International Meeting. May 31-June 4, 2014; Montreal, QC, Canada.

http://apps.humana.com/marketing/documents.asp?file=2573987

Using sequence discovery to target outreach for diabetes medication adherence

Lopez A, Long CL, Happe LE, Relish M. Using sequence discovery to target outreach for diabetes medication adherence. Am J Manag Care. 2015;21(11):e601-e608

Using sequence discovery to target outreach for diabetes medication adherence. - PubMed - NCBI